Lv3
318 积分 2025-02-10 加入
Tarlatamab for Patients with Previously Treated Small-Cell Lung Cancer
56分钟前
待确认
Anlotinib as third- or further-line therapy for short-term relapsed small-cell lung cancer: subgroup analysis of a randomized phase 2 study (ALTER1202)
1小时前
已完结
Italian, Multicenter, Phase III, Randomized Study of Cisplatin Plus Etoposide With or Without Bevacizumab as First-Line Treatment in Extensive-Disease Small-Cell Lung Cancer: The GOIRC-AIFA FARM6PMFJM Trial
2小时前
已完结
Toripalimab Plus Chemotherapy as a First-Line Therapy for Extensive-Stage Small Cell Lung Cancer
3小时前
已完结
Adebrelimab or placebo plus carboplatin and etoposide as first-line treatment for extensive-stage small-cell lung cancer (CAPSTONE-1): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial
3小时前
已完结
Durvalumab plus platinum–etoposide versus platinum–etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial
4小时前
已完结
Patient Understanding of Oncology Clinical Trial Endpoints in Direct-to-Consumer Television Advertising
7天前
已完结
Association between progression‐free survival and patients’ quality of life in cancer clinical trials
7天前
已完结
Biased Evaluation in Cancer Drug Trials—How Use of Progression-Free Survival as the Primary End Point Can Mislead
7天前
已完结
Accelerated Approval Is Not Conditional Approval
7天前
已完结
皖公网安备34019202002308
